Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Mar 14, 2023 2:20pm
177 Views
Post# 35337931

RE:RE:H.C. mainwright re- issues buy rating @ $15 USD for oncy

RE:RE:H.C. mainwright re- issues buy rating @ $15 USD for oncyPlay on context of wording.
they are using an assumption of 45% liklyhood of Pela working for mbc
As things get closer that % of likelihood would go up.
Without seeing the actual report, I can't comment on the 12% number.
my assumption is that it is of the same context.
i.e. Using 12% of the potential.
not 12% discount.
I'll look at RBC report which I can see.
they use similar analysis, different numbers.
realality?
a % point here or there, can change the target significantly.
when things hone in closer , then the numbers will have a much more meaningful representation.
All the analysts are trying to be as cautious as they can, to be close to correct.
june 2-6th hopefully gives everyone better clarity.
At his latest interview Matt was quite positive.

<< Previous
Bullboard Posts
Next >>